Summary & Overview
HCPCS J9601: Injection, linvoseltamab-gcpt, 1 mg
HCPCS Level II code J9601 designates an injectable biologic product: linvoseltamab-gcpt, billed per 1 mg. This code matters nationally as it standardizes claims submission for a targeted injectable therapy, enabling consistent reimbursement workflows and tracking of utilization for payers, providers, and federal programs. Clear coding supports patient access, coverage adjudication, and aggregation of utilization data across care settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, common clinical contexts for use, and typical sites where the product is administered. The publication outlines benchmarks and payment policy themes relevant to injectable biologics, highlights coding and billing implications for outpatient infusion and physician office settings, and summarizes documentation elements that influence claim acceptance.
The content provides a concise clinical and administrative context for J9601, explains why accurate HCPCS Level II coding is important for claims processing and program integrity, and points to areas where payers and providers commonly align or diverge on coverage and billing practices. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9601 represents an injection product described as linvoseltamab-gcpt, 1 mg. The code denotes a billed unit of the specified injectable biologic therapy.
Service Type: Injectable biologic administration
Typical Site of Service: Outpatient infusion or injection setting, including hospital outpatient departments, physician offices, and infusion centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 67-year-old patient with relapsed or refractory multiple myeloma is scheduled to receive linvoseltamab-gcpt therapy. The medication is supplied as an injectable monoclonal antibody dosed by milligram; billing uses J9601 per 1 mg. The patient presents to an outpatient oncology infusion center for administration. Prior to infusion, an oncologist or advanced practice provider performs a clinic visit to confirm diagnosis, prior treatments, baseline laboratory values (CBC, CMP), and eligibility. On the day of service, standard pre-infusion assessments include vital signs, evaluation for active infections, review of prior infusion reactions, and verification of infusion consent. Pharmacy prepares the weight- or dose-based syringe/vial and documents lot number and concentration; nursing performs IV access placement, medication administration per protocol, and continuous monitoring for infusion-related reactions and cytokine release syndrome during and after infusion. Post-infusion, the patient is observed for the specified monitoring period, instructed on signs/symptoms to report, and scheduled for follow-up laboratory testing and oncology visits to assess response and toxicities. Typical site of service is an outpatient hospital-based or freestanding infusion center; the service type is an injectable biologic/oncology infusion billed as a HCPCS Level II J-code for the drug product.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |